AbbVie presents compelling ovarian cancer data that could significantly expand ELAHERE’s market reach

AbbVie has recently presented their new late-breaking Phase 2 data showing its antibody-drug conjugate ELAHERE delivered a 62.7% objective response rate when combined with carboplatin chemotherapy in patients with platinum-sensitive ovarian cancer, a result described by the trial’s lead investigator as supporting further investigation of this treatment approach in a patient population that has historically had limited options following PARP inhibitor failure.

The data, presented in an oral session at the Society of Gynecologic Oncology Annual Meeting in San Juan, Puerto Rico, marks a meaningful step in AbbVie’s efforts to expand ELAHERE beyond its current approved indication. The drug is already FDA and EU approved for platinum-resistant ovarian cancer, a smaller and more heavily pre-treated patient group. Platinum-sensitive ovarian cancer represents a substantially larger population, and success in this setting would meaningfully broaden the drug’s addressable market and commercial potential.

The trial evaluated ELAHERE in combination with carboplatin for six cycles, followed by ELAHERE as a single-agent continuation therapy in patients whose disease did not progress. The study enrolled women whose tumours expressed folate receptor alpha at high levels, the molecular marker that ELAHERE is designed to target, and who had received one prior line of platinum-based chemotherapy.

Gottfried Konecny, Professor of Medicine at UCLA’s David Geffen School of Medicine and the trial’s principal investigator, said the combination delivered strong responses and that many patients continued to benefit during the monotherapy continuation phase. He noted the findings support further investigation of integrating ADC therapy with standard chemotherapy, particularly for patients previously treated with PARP inhibitors who often develop resistance and face limited subsequent treatment options.

Why This Matters for Investors

ELAHERE came to AbbVie through its acquisition of ImmunoGen in early 2024 for approximately $10 billion. At the time, AbbVie highlighted the drug’s expansion potential into earlier and larger segments of the ovarian cancer market as a central part of the deal’s strategic rationale. This Phase 2 data represents early but meaningful clinical validation of that thesis.

Ovarian cancer kills more than 200,000 women globally each year and remains one of the leading causes of death from gynaecological cancers worldwide. The platinum-sensitive segment, covering patients who initially responded to platinum-based treatment before relapsing, is considerably larger than the platinum-resistant setting where ELAHERE currently operates. An approved indication in this setting would place ELAHERE in direct competition for a much broader patient pool at an earlier and potentially more durable stage of treatment.

AbbVie has not yet announced plans for a Phase 3 trial in this setting, but the strength of the response rate and the selection of a late-breaking oral presentation slot, typically reserved for the most significant data at major oncology conferences, suggests the company is moving with intent.

---

---

Related Topics and Keywords

ABBV, AbbVie, AntibodyDrugConjugate, BiopharmInvesting, clinical trials, ELAHERE®, LabelExpansion, Ovarian Cancer, Phase2, platinum-resistant ovarian cancer, SGO2026